Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.
Nov 13, 2014
Ocera Reports Third Quarter 2014 Financial Results
Mar 2, 2015 at 4:50 PM ET
Cowen and Company Annual Health Care Conference